10x Genomics, Inc. TXG
59.10 USD -2.95 (-4.75%)
At closeNov 12, 2026, 4:00 PM EST
58.97 -0.13 -0.21%
After hours · Nov 12, 4:00 PM ET
53.00 Day range 60.37
15.12 52-week range 102.81
- YTD
- +262.35%
- 1 year
- +254.10%
News
zacks.com 10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.
benzinga.com 10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC)…
prnewswire.com Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG),…
benzinga.com JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65 JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.
benzinga.com Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70 Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.
marketbeat.com What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call Torex Gold Resources TSE: TXG reported a 37% quarter-over-quarter increase in production in the third quarter of 2026, as higher grades and improved gold recovery boosted margins and cash flow at its…
defenseworld.net 10x Genomics $TXG Stock: Chicago Partners Investment Group LLC Lowers Position Chicago Partners Investment Group LLC lowered its position in shares of 10x Genomics (NASDAQ: TXG) by 29.3% in the undefined quarter, according to the company in its most recent Form 13F filing with…- benzinga.com UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.
- benzinga.com Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60 Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.
zacks.com 10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
zacks.com TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook 10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
marketbeat.com What 10x Genomics (TXG) Said on Its Q3 Earnings Call 10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
benzinga.com Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68 Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $68.
fool.com Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026 Small-cap stocks have benefited from a range of tailwinds this year.
benzinga.com 10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est 10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $610.000 million-$630.000 million to $625.000 million-$635.000 million vs $619.854 million estimate.
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70 TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.- benzinga.com Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70 Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $40 to $70.